News and Press Releases
Exonate first-in-class eye drop phase 1b/2a trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully supports continued clinical development of EXN407...
Category: Clinical Trials
Posted: March 5, 2024
Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications of Their Phase 1/2a Trial of an Intratympanic Gamma Secretase Inhibitor for the Treatment of Mild to Moderate Sensorineural Hearing Loss
The phase 1 part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480 Pre-defined Primary...
Category: Clinical Trials
Posted: March 4, 2024
Linnaeusparkweg 10-2, 1098 EA Amsterdam, Netherlands
SolasCure Publishes Phase 2a Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the phase 2a trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase...
Category: Biotechnology
Posted: March 4, 2024
WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges
4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...
Category: Clinical Trials
Posted: March 4, 2024
Aotearoa Clinical Trials Becomes First Site in New Zealand to Achieve both GCSA Certification and Silver Workforce Quality Accreditation
Certifications demonstrate Aotearoa Clinical Trials is working to the highest global best-practice standards, ratified by the industry 21 February 2024 -- Auckland, New Zealand and Maidenhead, UK -- Aotearoa Clinical Trials...
Category: Clinical Trials
Posted: February 21, 2024
Esme Green Building Middlemore Hospital 100 Hospital Rd Papatoetoe, 2025 Auckland, New Zealand
Principal IRB Becomes Univo IRB With Support From QHP Capital
20 February 2024 -- North Carolina -- Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired...
Category: Clinical Trials
Posted: February 20, 2024
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT (amivantamab), in combination with Lazertinib, for the First-Line Treatment of Patients with EGFR Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with...
Category: Drug Discovery
Posted: February 8, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services
Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...
Category: Clinical Trials
Posted: February 1, 2024
Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK
25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...
Category: Pharmaceutical
Posted: January 25, 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...
Category: Clinical Trials
Posted: January 16, 2024
Headlands Research Announces Partnership with Sahara Behavioral Health
The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...
Category: Clinical Trials
Posted: January 5, 2024
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...
Category: Clinical Trials
Posted: January 5, 2024
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO CongressLazertinib is a highly selective, central...
Category: Clinical Trials
Posted: December 21, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
